EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's [Yahoo! Finance]
Alzamend Neuro, Inc. (ALZN)
Company Research
Source: Yahoo! Finance
data set from its multiple ascending dose clinical trial for AL001 for dementia related to Alzheimer's. Preliminary results were released in June 2023 Identified by an independent safety review committee, this MTD represents a pivotal step forward; it delivers lithium at a lithium carbonate equivalent dose of 240 mg, taken three times daily (TID). The Phase 2A study evaluated the safety and tolerability of AL001 under multiple-dose, steady-state conditions. It determined the MTD in patients diagnosed with mild to moderate Alzheimer's disease and in healthy non-elderly and elderly subjects with adequate renal function. Lithium has been well characterized for safety and is approved and marketed in multiple formulations for bipolar disorder. The safety profile was demonstrated to be benign at all dose levels. The dose level chosen for further development was based on avoiding plasma drug concentrations associated in the medical literature with exceeding the upper limit of the t
Show less
Read more
Impact Snapshot
Event Time:
ALZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALZN alerts
High impacting Alzamend Neuro, Inc. news events
Weekly update
A roundup of the hottest topics
ALZN
News
- Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’sBusiness Wire
- Alzamend Neuro regains compliance with Nasdaq [Seeking Alpha]Seeking Alpha
- Alzamend Neuro Regains Compliance with Nasdaq Listing StandardsBusiness Wire
- Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare ConferenceBusiness Wire
- Alzamend Neuro Issues Letter to StockholdersBusiness Wire
ALZN
Sec Filings
- 10/15/24 - Form 8-K
- 10/3/24 - Form 424B5
- 10/3/24 - Form 8-K
- ALZN's page on the SEC website